Sanofi and Voyager Therapeutics Enter into Gene Therapy R&D Partnership

Sanofi’s subsidiary Genzyme is showing its faith in gene therapy for neurodegenerative diseases in an $845 million deal with biotechnology startup Voyager Therapeutics. Under the partnership, Genzyme has the option to license several of Voyager’s therapeutic programs once the proof-of-concept clinical trials are complete. Voyager’s ALS program is outside the scope of this partnership, but the investment from Genzyme will help the startup advance its clinical stage adeno-associated virus (AAV) based therapy for Parkinson’s disease through Phase I and give a boost to preclinical studies in other therapeutic areas.

Sanofi’s subsidiary Genzyme is showing its faith in gene therapy for neurodegenerative diseases in an $845 million deal with biotechnology startup Voyager Therapeutics. Under the partnership, Genzyme has the option to license several of Voyager’s therapeutic programs once the proof-of-concept clinical trials are complete. Voyager’s ALS program is outside the scope of this partnership, but the investment from Genzyme will help the startup advance its clinical stage adeno-associated virus (AAV) based therapy for Parkinson’s disease through Phase I and give a boost to preclinical studies in other therapeutic areas.

Click here to read more.

disease-ad disease-pd topic-clinical topic-preclinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail